Status:
COMPLETED
1-Week Dispensing Evaluation of Kalifilcon A Daily Disposable Multifocal Compared to Ultra for Presbyopia
Lead Sponsor:
Bausch & Lomb Incorporated
Conditions:
Presbyopia
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
Experienced soft contact lens wearing subjects will be enrolled in this 1-week, confirmatory, randomized, bilateral, 2-way crossover, double masked (subject and investigator), repeated measures, dispe...
Eligibility Criteria
Inclusion
- Be 40 years or older on the date the Informed Consent Form (ICF) is signed and have the capacity to read, understand and provide written voluntary informed consent.
- Have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings.
- Have no active ocular disease or allergic conjunctivitis.
- Not be using any topical ocular medications.
- Be willing and able to follow instructions.
- Have signed a statement of informed consent.
Exclusion
- Participating in a conflicting study.
- Considered by the Investigator to not be a suitable candidate for participation.
Key Trial Info
Start Date :
February 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 28 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05325931
Start Date
February 25 2022
End Date
March 28 2022
Last Update
April 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bausch site 1
Rochester, New York, United States, 14609